Regarding rumors of an imminent approval of lecanemab in Great Britain: BioArctic
BioArctic AB (NASDAQ Stockholm: BIOA B) has addressed recent rumors circulating in British media regarding the imminent approval of lecanemab in Great Britain. The company stated that it has not been informed of any decision made by the relevant authorities and is therefore unable to comment on these speculations. BioArctic has committed to updating the market if new information becomes available. This statement was released for public disclosure on August 22, 2024, at 08:34 a.m. CET. The company has provided contact information for its VP of Communications and IR, Oskar Bosson, for further inquiries.
BioArctic AB (NASDAQ Stockholm: BIOA B) ha affrontato recenti voci circolanti nei media britannici riguardo l'approvazione imminente di lecanemab nel Regno Unito. L'azienda ha dichiarato di non essere stata informata di alcuna decisione presa dalle autorità competenti e pertanto è incapace di commentare queste speculazioni. BioArctic si è impegnata a aggiornare il mercato se nuove informazioni diventeranno disponibili. Questa dichiarazione è stata rilasciata per la divulgazione pubblica il 22 agosto 2024, alle 08:34 CET. L'azienda ha fornito informazioni di contatto per il suo VP delle Comunicazioni e IR, Oskar Bosson, per ulteriori domande.
BioArctic AB (NASDAQ Estocolmo: BIOA B) ha abordado rumores recientes que circulan en los medios británicos sobre la inminente aprobación de lecanemab en Gran Bretaña. La empresa declaró que no ha sido informada de ninguna decisión tomada por las autoridades correspondientes y, por lo tanto, es incapaz de comentar sobre estas especulaciones. BioArctic se ha comprometido a actualizar al mercado si nueva información está disponible. Esta declaración se publicó para divulgación pública el 22 de agosto de 2024, a las 08:34 CET. La empresa ha proporcionado información de contacto para su VP de Comunicaciones e IR, Oskar Bosson, para consultas adicionales.
BioArctic AB (NASDAQ 스톡홀름: BIOA B)는 영국 언론에서 lecanemab의 곧 승인이 이루어질 것이라는 최근의 소문에 대해 입장을 밝혔습니다. 회사는 관련 당국에 의해 어떤 결정도 통보받지 않았다고 밝혔으며, 따라서 이러한 추측에 대해 댓글을 할 수 없다고 전했습니다. BioArctic는 새로운 정보가 생길 경우 시장에 업데이트할 것을 약속했습니다. 이 성명서는 2024년 8월 22일, CET 오전 08:34에 공개적으로 발표되었습니다. 회사는 추가 문의를 위한 커뮤니케이션 및 IR 담당 부사장 Oskar Bosson의 연락처 정보를 제공했습니다.
BioArctic AB (NASDAQ Stockholm: BIOA B) a répondu aux rumeurs récentes circulant dans les médias britanniques concernant l'approbation imminente de lecanemab en Grande-Bretagne. L'entreprise a déclaré qu'elle n'avait pas été informée d'une décision prise par les autorités compétentes et qu'elle était donc dans l'incapacité de commenter ces spéculations. BioArctic s'est engagé à mettre à jour le marché si de nouvelles informations deviennent disponibles. Cette déclaration a été publiée pour diffusion publique le 22 août 2024 à 08h34 CET. L'entreprise a fourni des informations de contact pour son VP des communications et des relations investisseurs, Oskar Bosson, pour toute question supplémentaire.
BioArctic AB (NASDAQ Stockholm: BIOA B) hat sich zu aktuellen Gerüchten in den britischen Medien geäußert, die die bevorstehende Genehmigung von lecanemab im Vereinigten Königreich betreffen. Das Unternehmen erklärte, dass es nicht informiert wurde über eine Entscheidung der zuständigen Behörden und daher nicht zu diesen Spekulationen Stellung nehmen kann. BioArctic hat sich verpflichtet, den Markt zu aktualisieren, falls neue Informationen verfügbar werden. Diese Erklärung wurde am 22. August 2024 um 08:34 Uhr CET zur öffentlichen Bekanntgabe veröffentlicht. Das Unternehmen hat Kontaktinformationen für seinen VP für Kommunikation und IR, Oskar Bosson, für weitere Anfragen bereitgestellt.
- None.
- None.
Insights
While rumors of lecanemab's approval in Great Britain are circulating, it's important to approach this information cautiously. Lecanemab, an antibody targeting amyloid beta, has shown promise in treating Alzheimer's disease. However, BioArctic's statement clearly indicates no official confirmation from regulatory authorities. This situation highlights the delicate nature of drug approval processes and the potential impact of premature information on investor sentiment.
Investors should be aware that drug approvals can significantly influence biotech stock valuations. If approved, lecanemab could represent a major advancement in Alzheimer's treatment, potentially boosting BioArctic's market position. However, until official confirmation, it's prudent to remain cautious and monitor official channels for verified information.
BioArctic's swift response to market rumors demonstrates strong corporate governance and transparency. This proactive communication strategy is important in maintaining investor trust, especially in the volatile biotech sector. While the potential approval of lecanemab could be a game-changer for BioArctic, investors should exercise caution.
The lack of official confirmation means the stock price might experience volatility based on speculation. It's important to note that even if approved, factors such as pricing, market adoption and competition will play important roles in the drug's commercial success. Investors should focus on official announcements and upcoming financial reports to gauge the true impact on BioArctic's financial health and growth prospects.
The information was released for public disclosure, through the agency of the contact persons below, on August 22, 2024, at 08.34 a.m. CET.
For further information, please contact:
Oskar Bosson, VP Communications and IR
E-mail: oskar.bosson@bioarctic.se
Phone: +46 70 410 71 80
About BioArctic AB
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with BioArctic's partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit www.bioarctic.com.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Regarding rumors of an imminent approval of lecanemab in |
View original content:https://www.prnewswire.com/news-releases/regarding-rumors-of-an-imminent-approval-of-lecanemab-in-great-britain-bioarctic-302228382.html
SOURCE BioArctic
FAQ
What are the rumors about lecanemab approval in Great Britain that BioArctic (BIOA) is addressing?
Has BioArctic (BIOA) received official confirmation about lecanemab's approval in Great Britain?
When did BioArctic (BIOA) release the statement about lecanemab approval rumors?
How will BioArctic (BIOA) handle new information about lecanemab's approval status in Great Britain?
